Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension-Reference-Cited by-同舟云学术

Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension

Published:2016-08-19 Issue:17 Volume:59 Page:7901-7914
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Shaw Duncan E.¹,Baig Ferheen,Bruce Ian,Chamoin Sylvie²,Collingwood Stephen P.,Cross Sarah¹,Dayal Satish,Drückes Peter²,Furet Pascal²,Furminger Vikki,Haggart Deborah³,Hussey Martin,Konstantinova Irena,Loren Jon C.³,Molteni Valentina³,Roberts Sonia,Reilly John,Saunders Alex M.,Stringer Rowan,Sviridenko Lilya,Thomas Matthew,Thomson Christopher G.¹,Tomlins Christine,Wen Ben³,Yeh Vince³,Pearce Andrew C.

Affiliation:

1. Novartis Institutes of Biomedical Research (NIBR), 100 Technology Square, Cambridge, Massachusetts 02139, United States

2. NIBR, Basel Fabrikstrasse 2, 4056 Basel, Switzerland

3. Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00703

Reference22 articles.

1. Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension